Century Therapeutics, Inc.
IPSCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Century Therapeutics, Inc. focuses on Biotechnology services and products. Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. The $405.8M market capitalization puts IPSC squarely in small-cap range for its industry. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Market Cap
$405.8M
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
-4.92
EPS (TTM)
$-1.13
EPS (Fwd)
$-0.46
ROE
-42.7%
ROA
-22.3%
Cash
$134.8M
Total Debt
$48.0M
Free CF
-$53.6M
52W Change
287.3%
Annual Financials
Cash vs Debt
With $134.8M in cash and $48.0M in debt, IPSC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$53.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.2M (2022) to $109.2M (2025), reflecting a 2000% increase over the period.
Century Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IPSC.